Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Votan2015on Mar 29, 2020 9:49am
92 Views
Post# 30857229

RE:RE:Great article

RE:RE:Great article
polygraph46 wrote: SKL...I just read the Health Europa report about Kaly as stated by Dr. Sari Sagiv, CSO Kaly.

In reading paras #12(or thereabouts) Sagiv states "at this statge Kaly are ready to plan a meeting with FDA to discuss the possibility of starting a pivotal study later this year" unquote.
 What comes to your mind when see terminology like as above..."ready to plan"....."discuss the possibility"?  For me, I see vagueness and little or no meat.  Theres nothing forthright about what they will do!!

 Now, couple the above comments with what Robert Farrell news released Aug 2019...."we will proceed directly and initiate phase 3 study".  That promising statement was some seven mos. ago.
Where is Robert Farrell these days?  He is M.I.A.  Looks like he's pulled a Houdini as there no response from him to pointed questions.  We all should be wanting direct and solid answers fr. him.

Like I posted around this same time back on March 25th, we are being fed a line.
The above, in my humble opinion, along with the proposed share consolidation and mistyfying purchase of Stero......... stinks.
It stinks like four day old Haddock filets. And, I know good seafood as I live out here on the East Coast, Nova Scotia to be exact.  I am simply espressing my opinion here, nothing more.....pg46   
 






They know what we think about the whole deal and She released that article to pacify people's anger and doubts about their intentions. I see it as another way to manipulate us and believe them.
Bullboard Posts